American Oriental Bioengineering Accounts Payable

American Oriental Bioengineering posts a accounts payable of $7.4M as of September 2013. That compares with $24M in the prior-year period — down 69.3% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, American Oriental Bioengineering's accounts payable was $24M. The latest reading is $7.4M — a 69.3% year-over-year decrease (period ending September 2013). Use the history and growth charts on this page for a longer lookback.

Accounts Payable is one piece of American Oriental Bioengineering's financial statement story. At $7.4M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for AOBI's accounts payable usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; American Oriental Bioengineering's other metric pages and overview cover the third.

Judging American Oriental Bioengineering against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in accounts payable easier to interpret. Start with $7.4M here, then scan peer and history charts to see if the gap is persistent.